Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 6/20 | 0.60 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 8/20 | 0.51 |
| ▸ | PPARA | Q07869 | 8/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3976394 | 0.91 | NR1H2 (0.66) | NR1H2NR1H3KDRPPARGPPARA | |
| SCHEMBL3981452 | 0.90 | NR1H2 (0.60) | NR1H2NR1H3KDRPPARGPPARA | |
| SCHEMBL3978225 | 0.90 | KDR (0.54) | NR1H2NR1H3KDRPPARGPPARA | |
| SCHEMBL3978463 | 0.87 | NR1H2 (0.61) | NR1H2NR1H3KDRPPARGPPARA | |
| SCHEMBL3980129 | 0.87 | NR1H2 (0.65) | NR1H2NR1H3KDRPPARGPPARA | |
| SCHEMBL3981024 | 0.84 | PPARG (0.51) | NR1H2NR1H3KDRPPARGPPARA | |
| SCHEMBL3980064 | 0.83 | MAPT (0.54) | KDRPPARGPPARACYP2C9KCNH2 | |
| SCHEMBL3975942 | 0.82 | KDR (0.49) | NR1H2NR1H3KDRPPARGPPARA | |
| SCHEMBL3976645 | 0.81 | MAPT (0.54) | KDRPPARGPPARACYP2C9KCNH2 | |
| SCHEMBL3982502 | 0.81 | PPARG (0.51) | KDRPPARGPPARACYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101031540-B | Hexafluoroisopropanol substituted ether derivatives | HOFFMANN LA ROCHE | 2010-05-26 | — | — | CN | claimed |
| US-7473705-B2 | Hexafluoroisopropanol substituted ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-01-06 | — | — | US | claimed |
| EP-1802566-B1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-11-26 | — | — | EP | claimed |
| CN-101031540-A | Hexafluoroisopropanol substituted ether derivatives | HOFFMANN LA ROCHE (CH) | 2007-09-05 | — | — | CN | claimed |
| EP-1802566-A1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-07-04 | — | — | EP | claimed |
| WO-2006037480-A1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | claimed |
| US-20060074115-A1 | Novel hexafluoroisopropanol substituted ether derivatives | HOFFMANN-LA ROCHE INC. | 2006-04-06 | — | — | US | claimed |
| CN-101031540-B | Hexafluoroisopropanol substituted ether derivatives | HOFFMANN LA ROCHE | 2010-05-26 | — | — | CN | disclosed |
| US-7473705-B2 | Hexafluoroisopropanol substituted ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-01-06 | — | — | US | disclosed |
| EP-1802566-B1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-11-26 | — | — | EP | disclosed |
| CN-101031540-A | Hexafluoroisopropanol substituted ether derivatives | HOFFMANN LA ROCHE (CH) | 2007-09-05 | — | — | CN | disclosed |
| EP-1802566-A1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006037480-A1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | disclosed |
| US-20060074115-A1 | Novel hexafluoroisopropanol substituted ether derivatives | HOFFMANN-LA ROCHE INC. | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074115-A1 | Novel hexafluoroisopropanol substituted ether derivatives | NR1H3, NR1H2, NR1I2 | NR1H2 2/4885NR1H3 1/4885KDR 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.